Reagan Jarvis
Chief Executive Officer & Co-Founder Anocca AB
Reagan Jarvis is the Co-Founder and CEO of Anocca, a T-cell immunotherapy company based out of Sweden, commencing first-in-human clinical trials in 2025 with gene-edited TCR-T cell therapy products in oncology. A New Zealander, Jarvis obtained his PhD in Biochemistry at University of Otago and performed postdoctoral research at the University of Otago and thereafter the German Cancer Research Center (DKFZ) in Heidelberg. He founded Anocca with Mikael Blomqvist in 2014. Anocca currently has a pipeline of over 40 products. It has 130+ staff, with 40+ nationalities and operates its own cGMP cell therapy manufacturing site in Södertälje, south of Stockholm.
Seminars
Wednesday 9th September 2026
Panel Discussion: Setting the Boundaries of What’s Clinically Achievable in RAS Therapy Defining the Realistic Therapeutic Window for Next-Generation Strategies
3:30 pm
- How does differential targeting influence tolerability and depth of pathway inhibition, and where do selective versus broader approaches ultimately succeed or fail?
- How should mutant-selective versus wild-type-sparing strategies be balanced to deepen inhibition without breaching tolerability limits, especially when layering multi-agent regimens?
- How can safety-first design principles, PK/PD-guided exposure management, mechanism-based toxicity mitigation, and early integration of safety margins, enable continuous pathway suppression and long-term disease control?
Thursday 10th September 2026
Designing a Library of TCR T Cell Therapy Products that Precisely Target Mutant KRAS
9:30 am
- Selecting and validating high value KRAS targets systemized cell biology assays
- Defining potent and selective TCR assets that form the foundation of differentiated TCR T therapy products
- Scaling manufacturing and clinical trial design to enable meet the needs of highly personalized cell therapies
